The frequency of ER+ tumors in our study (68%, n = 19 out of 28) is slightly higher compared to breast cancer among young cases in the general population (50–60%) [15,17], but is consistent with what was reported by Broeks et al. in the study of breast cancer after HL [9]. The gene discussed is ESR1; the disease is breast cancer.